lung

Respilean Drops Exposed (MUST-READ): The Truth About Lung Support Big Pharma Doesnt Want You to KnowRespilean Drops Exposed (MUST-READ): The Truth About Lung Support Big Pharma Doesnt Want You to Know

Respilean Drops Exposed (MUST-READ): The Truth About Lung Support Big Pharma Doesnt Want You to Know

JUPITER, FLORIDA, April 02, 2025 (GLOBE NEWSWIRE) --  RESPILEAN In a world where we measure everything—from step counts to calories—there’s…

3 weeks ago
Canadas Big Tobacco Settlement Falls Short: Provinces Face a Massive Financial Gap in Covering Tobacco-Related Costs, Says National Lung Health AllianceCanadas Big Tobacco Settlement Falls Short: Provinces Face a Massive Financial Gap in Covering Tobacco-Related Costs, Says National Lung Health Alliance

Canadas Big Tobacco Settlement Falls Short: Provinces Face a Massive Financial Gap in Covering Tobacco-Related Costs, Says National Lung Health Alliance

TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- The National Lung Health Alliance (NLHA) acknowledges today’s approval of Canada’s $32.5 billion…

2 months ago
National Non-Smoking Week: A Call to Breathe Easier by Starting the Quit Journey with Lung Health FoundationNational Non-Smoking Week: A Call to Breathe Easier by Starting the Quit Journey with Lung Health Foundation

National Non-Smoking Week: A Call to Breathe Easier by Starting the Quit Journey with Lung Health Foundation

TORONTO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- This week, Canadians from coast to coast will unite to celebrate National Non-Smoking…

3 months ago
Lung Health Foundation Announces New Leaders to Reshape Lung Healthcare in CanadaLung Health Foundation Announces New Leaders to Reshape Lung Healthcare in Canada

Lung Health Foundation Announces New Leaders to Reshape Lung Healthcare in Canada

January 16, 2025 10:00 ET  | Source: Lung Health Foundation TORONTO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- The Lung Health…

3 months ago
HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapyHUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy

HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…

4 months ago
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor TherapyHUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…

4 months ago